×

Analyst: Not 'worst case scenario' for drug industry

1:05 PM ET Tue, 7 March 2017

Michael Yee, RBC Capital Markets biotech analyst, weighs in on the biotech sector amid President Trump's drug pricing concerns and GOP healthcare proposal.